22nd Century Group to Participate in the Emerging Growth Virtual Conference on July 17, 2024
22nd Century Group to Participate in the Emerging Growth Virtual Conference on July 17, 2024
Mocksville, North Carolina--(Newsfile Corp. - July 8, 2024) - 22nd Century Group, Inc. (NASDAQ: XXII), a tobacco products company focused on nicotine harm reduction and contract manufacturing, today announced that it will present at the Emerging Growth Virtual Conference on Wednesday, July 17, 2024 at 11:25 AM Eastern Time.
北卡羅來納州莫克斯維爾——（新聞稿社-2024年7月8日）——22世紀集團公司（NASDAQ: XXII），一家專注於尼古丁傷害減少和合同製造的菸草製品公司，今天宣佈將於2024年7月17日（週三）美國東部時間上午11:25參加新興增長虛擬會議。
To access the live presentation, please use the events link online at . Time permitting, questions may be included at the end of the presentation. Questions may be submitted in advance to Questions@EmergingGrowth.com.
若有時間，您可以通過在線活動鏈接訪問直播，演示結束時也可以提問。問題也可以提前提交到 Questions@EmergingGrowth.com。
About 22nd Century Group, Inc.
關於22世紀集團公司
22nd Century Group, Inc. (NASDAQ: XXII) is an agricultural biotechnology company focused on tobacco harm reduction, reduced nicotine tobacco and improving health and wellness through plant science. With dozens of patents allowing it to control nicotine biosynthesis in the tobacco plant, the Company has developed proprietary reduced nicotine content (RNC) tobacco plants and cigarettes, which have become the cornerstone of the FDA's Comprehensive Plan to address the widespread death and disease caused by smoking. The Company received the first and only FDA Modified Risk Tobacco Product (MRTP) authorization for a combustible cigarette in December 2021. The Company is a subsequent participating manufacturer under the Master Settlement Agreement ("MSA") and vertically integrated for the production of its own products plus contract manufacturing operations ("CMO"), which consist primarily of branded filtered cigars and conventional cigarettes.
22世紀集團公司（NASDAQ: XXII）是一家農業生物技術公司，專注於菸草危害減少、降低尼古丁含量的菸草和通過植物科學改善健康和福祉。該公司擁有數十項專利，可控制菸草植物中的尼古丁生物合成，已開發出專有的降低尼古丁含量（RNC）菸草植物和香菸，成爲FDA應對菸草死亡和疾病（FDA Comprehensive Plan）的基石。該公司於2021年12月獲得了首個也是唯一的FDA修改風險菸草產品（MRTP）授權可燃菸捲。除生產自己的產品外，該公司還是Master Settlement Agreement（“MSA”）下的後續參與生產商，垂直整合了合同製造業務（“CMO”），主要包括品牌過濾雪茄和傳統香菸。
Learn more at xxiicentury.com, on Twitter, on LinkedIn, and on YouTube.
了解更多信息，請訪問xxiicentury.com，在Twitter、LinkedIn和YouTube上了解更多信息。
Learn more about VLN at tryvln.com.
了解有關VLN的更多信息，請訪問 tryvln.com。
Investor Relations & Media Contact
Matt Kreps
Investor Relations
22nd Century Group
mkreps@xxiicentury.com
214-597-8200
投資者關係與媒體聯繫
Matt Kreps
投資者關係
22世紀集團
mkreps@xxiicentury.com
214-597-8200
譯文內容由第三人軟體翻譯。